Although media reports have speculated about the connection between heartburn treatments and cancer, no existing study conclusively links extended use of over-the-counter or prescription acid-reducing medication to increased incidence of esophageal cancer.

A recent study from the U.K. examined the treatment histories of people with and without esophageal cancer. Researchers found that patients whose gastroesophageal reflux disease (GERD) symptoms, inflammation of the esophagus or Barrett’s esophagus were treated with acid-suppressive drugs such as H2 blockers (like Pepcid® AC and Zantac®) or proton pump inhibitors (PPIs) were more likely to have cancer than those whose other gastric or intestinal problems were treated with the same drugs.

This doesn’t mean that acid-suppressive drugs increase the risk of esophageal cancer. The researchers concluded that the underlying condition (GERD or Barrett’s) is the actual risk for cancer, not the medications being used, which have proved safe and effective for many years.

For long-term treatment of GERD and acid-related conditions, it’s important to maintain a regular and ongoing discussion with your health-care professional. Patients using over-the-counter medications should follow label instructions that direct them to consult a physician if heartburn symptoms persist after 14 days of use.

* Pepcid® AC is a registered trademark of Johnson & Johnson-Merck Consumer Pharmaceuticals Co. Zantac® is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc.

The material in this site is intended to be of general informational use and is not intended to constitute medical advice, probable diagnosis or recommended treatments. OTC PPIs are only indicated for treatment of frequent heartburn. For severe heartburn or heartburn that persists after trying over-the-counter treatment or lifestyle modifications, visit your doctor to determine the right treatment for you. See the Terms and Conditions for more information.